c-ABL-IN-5

• UNSPSC Description:

  c-ABL-IN-5 is a selective c-Abl inhibitor with neuroprotective effects. c-ABL-IN-5 has blood-brain barrier penetrability, metabolic stability and good pharmacokinetic properties. When c-ABL-IN-5 is labeled with [18F] (compound [18F]3), it can be used as a tracer to evaluate disease-modifying efficacy by complementary positron emission tomography (PET). c-ABL-IN-5 can be used in the study of neurodegenerative diseases such as Parkinson's disease (PD)[1].

• Target Antigen:

  Bcr-Abl

• Type:

  Reference compound

• Related Pathways:

  Protein Tyrosine Kinase/RTK

• Applications:

  Neuroscience-Neurodegeneration

• Field of Research:

  Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/c-abl-in-5.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(NC1=CN2C=C(C=CC2=N1)C3=CC=CC=C3CCF)[C@H]4[C@H](C4)F

• Molecular Weight:

  341.35

• References & Citations:

  [1]Stéen EJL, et al. Development of 18F-Labeled PET Tracer Candidates for Imaging of the Abelson Non-receptor Tyrosine Kinase in Parkinson's Disease. J Med Chem. 2023 Sep 15.. .

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported